Groundbreaking 3D bioprinting systems for improving global health
Jetbio has been established to commercialise Newcastle University’s patented and groundbreaking 3D bioprinting technology. The company’s reactive jet impingement (ReJI) bioprinting technology creates fast, accurate, flexible and user-friendly systems for printing biomimetic cell filled gels for use in developing in vitro disease models for drug testing, and to support tissue engineering and regenerative medicine applications.
3D bioprinting is a promising technique for drug discovery because it can create models that more closely mimic human organs and tissues than traditional methods. These models can help identify potential drug side effects and can greatly reduce the time it takes to develop pharmaceutical treatments to ensure that ineffective drug compounds are eliminated from on-going drug development.
The company’s team combine a blend of skills in bioprinting research, manufacturing engineering, biomaterials and global business development. Collaborative projects with organisations has already delivered and validated the ReJI Jetbio technology with a number of end-users in industry and academic research resulting in Jetbio technology that will deliver robust 3D bioprinters and bioink products with high performance and competitive pricing.
10 million people in the UK have Osteoarthritis (OA), an estimated 5.4 million people have knee OA, and an estimated 3.2 million people have hip OA. (Source: Versus Arthritis)
Patented tech
Bioprinting patent granted in Europe and the USA, underpinned by years of Team know-how that is turning research into practical solutions.
In-house engineering
State of the art facilities and in-house product design, manufacture and quality management.
Fast and accurate
Improves the quality of cell-cell and cell-ECM interactions, giving a 3D cell culture which matures faster, has superior mechanical properties and enhanced biological function.
Sustainable Tissue Engineering
Working locally and globally with researchers to replace, refine and reduce (3Rs) the use of animals in research and testing.
Bioconvergent
Expertise in bringing together biological materials, engineering hardware, software and knowledge-driven healthcare applications, built on world-class scientific research.
Solutions Led
Jetbio collaborates with End-User Partners to leverage many years of research into practical and robust 3D bioprinting solutions.
Investing and developing our technology
With customers in mind! In 2025, we are installing Jetbio 3D bioprinting systems at End-User sites for product validation and applications testing to ensure commercially-viable 3D bioprinting solutions that are scalable, robust and user-friendly to operate.
